An EU approval for Shire's attention-deficit hyperactivity disorder (ADHD) drug Venvanse (lisdexamfetamine dimesylate) is edging closer after the UK's medicines regulator, the MHRA agreed to act the reference member state under the decentralised procedure. The drug was first approved in the US back in February 2007 under the name Vyvanse.
The firm was unavailable to comment on why it had taken so long to seek EU approval. The drug is available in the US and Canada for ADHD patients aged...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?